Literature DB >> 19706617

Cryptic exon activation by disruption of exon splice enhancer: novel mechanism causing 3-methylcrotonyl-CoA carboxylase deficiency.

Martin Stucki1, Terttu Suormala, Brian Fowler, David Valle, Matthias R Baumgartner.   

Abstract

3-Methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine catabolism. MCC is a heteromeric mitochondrial enzyme composed of biotin-containing alpha (MCCA) and smaller beta (MCCB) subunits encoded by MCCA and MCCB, respectively. We report studies of the c.1054G-->A mutation in exon 11 of MCCB detected in the homozygous state in a patient with MCC deficiency. Sequence analysis of MCCB cDNA revealed two overlapping transcripts, one containing the normal 73 bp of exon 11 including the missense mutation c.1054G-->A (p.G352R), the other with exon 11 replaced by a 64-bp sequence from intron 10 (cryptic exon 10a) that maintains the reading frame and is flanked by acceptable splice consensus sites. In expression studies, we show that both transcripts lack detectable MCC activity. Western blot analysis showed slightly reduced levels of MCCB using the transcript containing the missense mutation, whereas no MCCB was detected with the transcript containing the cryptic exon 10a. Analysis of the region harboring the mutation revealed that the c.1054G-->A mutation is located in an exon splice enhancer sequence. Using MCCB minigene constructs to transfect MCCB-deficient fibroblasts, we demonstrate that the reduction in utilization of exon 11 associated with the c.1054G-->A mutation is due to alteration of this exon splice enhancer. Further, we show that optimization of the weak splice donor site of exon 11 corrects the splicing defect. To our knowledge, this is the first demonstration of a point mutation disrupting an exon splice enhancer that causes exon skipping along with utilization of a cryptic exon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706617      PMCID: PMC2781441          DOI: 10.1074/jbc.M109.050674

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes.

Authors:  H X Liu; L Cartegni; M Q Zhang; A R Krainer
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

Review 2.  Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases.

Authors:  B J Blencowe
Journal:  Trends Biochem Sci       Date:  2000-03       Impact factor: 13.807

3.  The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency.

Authors:  M R Baumgartner; S Almashanu; T Suormala; C Obie; R N Cole; S Packman; E R Baumgartner; D Valle
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Multiple splicing defects in an intronic false exon.

Authors:  H Sun; L A Chasin
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity.

Authors:  L A Metherell; S A Akker; P B Munroe; S J Rose; M Caulfield; M O Savage; S L Chew; A J Clark
Journal:  Am J Hum Genet       Date:  2001-07-20       Impact factor: 11.025

Review 6.  The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders.

Authors:  N Gregersen; P Bross; B S Andrese; C B Pedersen; T J Corydon; L Bolund
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 7.  Sorting out the complexity of SR protein functions.

Authors:  B R Graveley
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

8.  A putative exonic splicing enhancer in exon 7 of the PDHA1 gene affects splicing of adjacent exons.

Authors:  C K Ridout; P Keighley; S Krywawych; R M Brown; G K Brown
Journal:  Hum Mutat       Date:  2008-03       Impact factor: 4.878

9.  Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.

Authors:  Aurélie Goyenvalle; Arran Babbs; Gert-Jan B van Ommen; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2009-05-19       Impact factor: 11.454

10.  RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events.

Authors:  Emanuele Buratti; Ashish Dhir; Marzena A Lewandowska; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2007-06-18       Impact factor: 16.971

View more
  9 in total

1.  Detailed molecular characterization of a novel IDS exonic mutation associated with multiple pseudoexon activation.

Authors:  L Grodecká; T Kováčová; M Kramárek; S Seneca; K Stouffs; C De Laet; F Majer; T Kršjaková; P Hujová; K Hrnčířová; P Souček; W Lissens; E Buratti; Tomas Freiberger
Journal:  J Mol Med (Berl)       Date:  2016-11-12       Impact factor: 4.599

Review 2.  Structure and function of biotin-dependent carboxylases.

Authors:  Liang Tong
Journal:  Cell Mol Life Sci       Date:  2012-08-07       Impact factor: 9.261

3.  3-methylcrotonyl-CoA carboxylase deficiency: clinical, biochemical, enzymatic and molecular studies in 88 individuals.

Authors:  Sarah C Grünert; Martin Stucki; Raphael J Morscher; Terttu Suormala; Celine Bürer; Patricie Burda; Ernst Christensen; Can Ficicioglu; Jürgen Herwig; Stefan Kölker; Dorothea Möslinger; Elisabetta Pasquini; René Santer; K Otfried Schwab; Bridget Wilcken; Brian Fowler; Wyatt W Yue; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

4.  Crystal structure of the alpha(6)beta(6) holoenzyme of propionyl-coenzyme A carboxylase.

Authors:  Christine S Huang; Kianoush Sadre-Bazzaz; Yang Shen; Binbin Deng; Z Hong Zhou; Liang Tong
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

5.  Consanguinity and rare mutations outside of MCCC genes underlie nonspecific phenotypes of MCCD.

Authors:  Peter J Shepard; Bruce A Barshop; Matthias R Baumgartner; John-Bjarne Hansen; Kristen Jepsen; Erin N Smith; Kelly A Frazer
Journal:  Genet Med       Date:  2014-11-06       Impact factor: 8.822

Review 6.  Role of pseudoexons and pseudointrons in human cancer.

Authors:  Maurizio Romano; Emanuele Buratti; Diana Baralle
Journal:  Int J Cell Biol       Date:  2013-09-24

7.  Splice-shifting oligonucleotide (SSO) mediated blocking of an exonic splicing enhancer (ESE) created by the prevalent c.903+469T>C MTRR mutation corrects splicing and restores enzyme activity in patient cells.

Authors:  Bruno Palhais; Veronica S Præstegaard; Rugivan Sabaratnam; Thomas Koed Doktor; Seraina Lutz; Patricie Burda; Terttu Suormala; Matthias Baumgartner; Brian Fowler; Gitte Hoffmann Bruun; Henriette Skovgaard Andersen; Viktor Kožich; Brage Storstein Andresen
Journal:  Nucleic Acids Res       Date:  2015-04-15       Impact factor: 16.971

8.  Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease.

Authors:  Erik van der Wal; Atze J Bergsma; Joon M Pijnenburg; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Mol Ther Nucleic Acids       Date:  2017-03-14

9.  Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.

Authors:  Niall P Keegan; Steve D Wilton; Sue Fletcher
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.772

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.